Annovis Bio, Inc. Receives Continued Listing Standard Notice From the NYSE
Annovis Bio, Inc. (ANVS)
Company Research
Source: GlobeNewswire
MALVERN, Pa., March 27, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced that on March 26, 2025, it received notice (the “Notice”) from the New York Stock Exchange (NYSE) that it is no longer in compliance with the NYSE continued listing standards set forth in Section 802.01B of the NYSE’s Listed Company Manual due to the fact that the Company’s average global market capitalization over a consecutive 30 trading-day period was less than $50 million while its stockholders’ equity was less than $50
Read more
Impact Snapshot
Event Time:
ANVS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ANVS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ANVS alerts
High impacting Annovis Bio, Inc. news events
Weekly update
A roundup of the hottest topics
ANVS
News
- AD/PD 2025: Buntanetap shows promise in early Parkinson's with mild dementia [Yahoo! Finance]Yahoo! Finance
- Annovis to Attend AD/PD™ 2025 with Extensive Scientific Program [Yahoo! Finance]Yahoo! Finance
- Annovis to Attend AD/PD™ 2025 with Extensive Scientific ProgramGlobeNewswire
- Annovis Provides Corporate Updates and Reports Fourth Quarter and Fiscal Year 2024 Financial ResultsGlobeNewswire
- Annovis Joins Experts at Drug Development Summit to Redefine Parkinson's Treatment [Yahoo! Finance]Yahoo! Finance
ANVS
Earnings
- 11/11/24 - Beat
ANVS
Sec Filings
- 3/27/25 - Form 8-K
- 3/21/25 - Form 10-K
- 3/21/25 - Form 8-K
- ANVS's page on the SEC website